Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes

Diabetes Care

Volumn 25, Issue 2, 2002, Pages 292-297

  Knowles, Negar G ^a   Landchild, Melinda A ^a   Fujimoto, Wilfred Y ^a   Kahn, Steven E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; IMMUNOREACTIVE INSULIN; AMYLOID; BIOLOGICAL MARKER; INSULIN;

ARTICLE; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; FAMILY HEALTH; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ADULT; DIET RESTRICTION; FAMILY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET; RISK FACTOR; STATISTICAL MODEL;

ADULT; AMYLOID; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FAMILY; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ISLETS OF LANGERHANS; LINEAR MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0036483682     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.2.292     Document Type: Article

References (49)

1. Kahn SE, Porte D Jr: Pathophysiology of type II diabetes mellitus. In Diabetes Mellitus. Porte D Jr, Sherwin RS, Eds. Stamford, CT, Appleton & Lange, 1996, p. 487-512
2. Porte D Jr: β-Cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
3. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:129-132, 1991
4. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97-102, 1992
5. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Fujimoto WY: Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645, 1998
6. Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J: Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297-1301, 1988
7. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225, 1988
8. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915, 1990
9. Martin BL, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992
10. Eriksson J, Franssila Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
11. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329:1988-1992, 1993
12. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467, 1981
13. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
14. Ryan EA, Imes S, Liu D, McManus R, Finegood DT, Polonsky KS, Sturis J: Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506-512, 1995
15. Larsson H, Ahren B: Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099-1107, 1996
16. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
17. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
18. Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK: Antepartum predictors of the development of type 2 diabetes in Latino women 11-26 months after pregnancies complicated by gestational diabetes. Diabetes 48:2430-2436, 1999
19. Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, Chang D, Chang J-K, Rizza RA: Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756, 1990
20. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE: Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 275:E785-E791, 1998
21. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci U S A 84:3881-3885, 1987
22. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
23. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289, 1990
24. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38:1333-1336, 1989
25. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194, 1994
26. Kautzky-Willer A, Thomaseth K, Ludvik B, Nowotny P, Rabensteiner D, Waldhausl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes 46:607-614, 1997
27. Prigeon RL, Kahn SE, Porte D Jr: Reliability of error estimates from the minimal model: implications for measurements in physiological studies. Am J Physiol 266:E279-E286, 1994
28. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677, 1979
29. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE: Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42:576-585, 1996
30. Rittenhouse J, Chait BT, Bierle JR, Janes SM, Park DR, Phelps JL, Fineman MS, Qin J, Koda JE: Heterogeneity of naturally-occurring human amylin due to glycosylation. Diabetes 45 (Suppl. 2):235A, 1996
31. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ Jr, Porte D Jr: Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 71:994-1002, 1990
32. Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K, Pedersen O: Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians: analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 98:1195-1209, 1996
33. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE: Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398-1403, 1999
34. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer J, Porte D Jr: The contribution of insulin dependent and insulin independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587-592, 1994
35. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN: Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19:1018-1030, 1996
36. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634-638, 1990
37. Landchild MJ, Knowles NG, Yao Q, Walden CE, Retzlaff BM, Knopp RH, Kahn SE: Increased β-cell secretory demand is not the simple explanation for inefficient proinsulin processing and islet amyloid formation in type 2 diabetes. J Invest Med 48:21A, 2000
38. Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P: Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240-244, 1989
39. O'Brien TD, Westermark P, Johnson KH: Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40:1701-1706, 1991
40. Gedulin B, Cooper GJS, Young AA: Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Commun 180:782-789, 1991
41. Kahn SE, Verchere CB, D'Alessio DA, Cook DL, Fujimoto WY: Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 36:570-573, 1993
42. DeFronzo RA: Glucose intolerance of aging: evidence for tissue insensitivity to insulin. Diabetes 28:1095-1101, 1979
43. Chen M, Bergman RN, Pacini G, Porte D Jr: Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 60:13-20, 1985
44. Mako ME, Starr JI, Rubenstein AH: Circulating proinsulin in patients with maturity-onset diabetes. Am J Med 63:865-869, 1977
45. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet i:293-295, 1989
46. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D Jr: Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253, 1990
47. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732, 1997
48. Kahn SE, Leonetti DL, Prigeon RL, Bergstrom RW, Fujimoto WY: Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44:173-179, 1995
49. Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Hales CN, Laakso M: Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia 38:1176-1182, 1995